The two mutations occur in a gene called ADAM10 - coding for an enzyme involved in processing the amyloid precursor protein - which now becomes the second
pathologically-confirmed gene for late-onset AD and the fifth AD gene overall.
Researchers from the Massachusetts General Hospital's MassGeneral Institute for Neurodegenerative Disease (MGH-MIND) found the two mutations in ADAM10 increase generation and accumulation of the toxic amyloid beta (A-beta) protein in the brains of a mouse model of AD.
The mutations also reduce generation of new neural cells in hippocampus, a part of the brain essential to learning and memory.
Also Read
"What we found regarding the many effects of these two rare mutations in ADAM10 strongly suggests that diminished activity of this enzyme can cause AD, and these findings support ADAM10 as a promising therapeutic target for both treatment and prevention," Tanzi said.
Researchers conducted experiments using several strains of transgenic mice and found that AD-associated mutations in ADAM10 reduced the release from neurons in the animals' brains of the beneficial protein produced by alpha-secretase processing of amyloid precursor protein (APP).
Also, reduced ADAM10 activity impaired the generation of new neurons in the hippocampus, one of the areas of the brain most vulnerable to neurodegeneration in AD.
The study will be published in the journal Neuron.